News

The results of the study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as part of an ASCO-sponsored press briefing. Eisai said that the

Opal Therapeutics is an immunotherapy development company focusing on novel therapies for HIV and Hepatitis C (HCV) based on proprietary technology licensed from the University of Melbourne. The

Benlysta is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognise and inhibit the biological activity

Marc Mansour, vice president of R&D at Immunovaccine, said: “Vaxil has an approach for identifying cancer antigens that get presented more efficiently by the MHC molecules. Vaxil’s long

Under this partnership, a portion of the on-campus molecular tracer laboratories of UW’s department of radiology will be relocated including one operated by John Grierson, who developed the

Ascenta Therapeutics and sanofi-aventis said that these orally-active, small-molecule drug candidates remove a block to normal p53 tumor suppressor function and inhibit the interaction between HDM2 (Human Double

PFC said that access to Maccabi’s multidimensional clinical database and patient registries are expected to reduce the risks of clinical research and shorten time to market. PFC and

Prednisporin is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx. CombinatoRx said that in addition to this $500,000 milestone, it will be eligible

Biomoda said that the Mexican patent #269352, ‘Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,’ is exactly